Gilead Sciences announced results from its Phase 3 (Study 114) study of cobicistat as a pharmaco-enhancing or “boosting” agent in the treatment of HIV. Study 114 is a randomized, double-blind, trial comparing the efficacy and safety of cobicistat-boosted atazanavir vs. ritonavir-boosted atazanavir, each administered with Truvada (emtricitabine and tenofovir disoproxil fumarate; Gilead Sciences), over a 96-week period. The trial met its 48-week primary objective of non-inferiority to ritonavir.

Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A).

For more information call (800) GILEAD-5 or visit www.gilead.com.